Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
BEDMINSTER, N.J. and SINGAPORE, Jan. 18, 2021 -- (Healthcare Sales & Marketing Network) -- Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, toda... Biopharmaceuticals, Oncology, Regulatory Tessa Therapeutics, CAR-T therapy, Hodgkin Lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Hematology | Lymphoma | Marketing | Pharmaceuticals | Singapore Health